ATLANTA, GA – – (Globe Newswire – August 6, 2026) – – A shareholder class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (“ARS”) (NASDAQ: SPRY). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts regarding ARS’s expected timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark.

If you purchased ARS shares between March 9, 2026 and June 24, 2026, and experienced a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/ars-pharmaceuticals/ for more information. 

 The deadline to ask the court to be appointed lead plaintiff in the case is October 5, 2026.